Legal & General Group
ELDN icon

Legal & General Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Legal & General Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.6K Buy
7,000
+1,667
+31% +$3.93K ﹤0.01% 2941
2025
Q4 		$8.05K Hold
5,333
– – ﹤0.01% 3288
2025
Q3 		$13.8K Hold
5,333
– – ﹤0.01% 3195
2025
Q2 		$14.5K Buy
+5,333
New +$16K ﹤0.01% 3141

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Legal & General Group's ELDN Position: Q1 2026 in Review

Legal & General Group increased its Eledon Pharmaceuticals (ELDN) stake by 31% in Q1 2026, buying an estimated $3.93K and bringing the position to 7,000 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

Legal & General Group first reported a position in ELDN in Q2 2025 and has held it in 4 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Legal & General Group held 7,000 shares of Eledon Pharmaceuticals worth $21.6K as of Q1 2026.
  • Legal & General Group bought 1,667 Eledon Pharmaceuticals shares in Q1 2026, an estimated $3.93K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2941 holding.
  • Legal & General Group first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.